专利检索 ap:("THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES") AND inv:"PERRY, Tracy, Ann" 第 1 页

1.

发明授权
GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF 有权
标题翻译： GLP-1肽类似物毒蜥外泌4及其用途

公开(公告)号：EP1411968B1

公开(公告)日：2008-09-17

申请号：EP02748271.0

申请日：2002-07-30

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： GREIG, Nigel, H. , EGAN, Josephine , DOYLE, Maire , HOLLOWAY, Harold , PERRY, Tracy, Ann

IPC分类号： A61K38/10 , A61K38/16 , C07K7/00 , C07K14/00 , C07K14/605 , A61K38/26

CPC分类号： C07K14/575 , A61K38/00 , A61K38/2278 , A61K38/26 , C07K14/57563

摘要： The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or extendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

2.

发明公开
GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF 有权
标题翻译： GLP-1肽类似物毒蜥外泌4及其用途

公开(公告)号：EP1411968A2

公开(公告)日：2004-04-28

申请号：EP02748271.0

申请日：2002-07-30

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： GREIG, Nigel, H. , EGAN, Josephine , DOYLE, Maire , HOLLOWAY, Harold , PERRY, Tracy, Ann

IPC分类号： A61K38/10 , A61K38/16 , C07K7/00 , C07K14/00

CPC分类号： C07K14/575 , A61K38/00 , A61K38/2278 , A61K38/26 , C07K14/57563

摘要： The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or extendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.